Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.

about

The Btk-dependent PIP5K1γ lipid kinase activation by Fas counteracts FasL-induced cell death.Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner.Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.

P2860

Q47298441-07BDA306-A8A8-4FED-9B6E-180265D2472F Q49339070-8737B3F3-CFC1-4D9F-8937-EAA7F13859F0 Q52645038-1A4C4A14-65BA-4548-8C54-4E21478BE361

P2860

Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.

Item

http://www.wikidata.org/entity/Q38766891

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.

@en

type

Item

label

Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.

@en

prefLabel

Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.

@en

P1476

Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells

@en

P2093

Christopher J Sevinsky

http://www.w3.org/2001/XMLSchema#string

Faiza Khan

http://www.w3.org/2001/XMLSchema#string

Jason Wong

http://www.w3.org/2001/XMLSchema#string

Leila Kokabee

http://www.w3.org/2001/XMLSchema#string

Xianhui Wang

http://www.w3.org/2001/XMLSchema#string

Yan Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer

Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking

KLF8 transcription factor participates in oncogenic transformation

Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases.

P304

2198-2208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-15-0813

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

D S Conklin

P577

2016-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27256378

http://www.w3.org/2001/XMLSchema#string

P932

5145257

http://www.w3.org/2001/XMLSchema#string

Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.

about

P2860

P2860

Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932